Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Athersys Inc New (EM) ATHXQ

Healthcare Biotechnology
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:ATHXQ)

Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 16, 2023

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

Business Wire October 16, 2023

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

Business Wire October 10, 2023

Athersys Licenses its Animal Health Assets to Ardent Animal Health

Business Wire October 3, 2023

Athersys Director Jane Wasman Appointed Board Chair

Business Wire October 2, 2023

Grant Awarded to Newcastle University to Research Athersys' MultiStem® in Machine Perfusion Prior to Kidney Transplantation

Business Wire September 6, 2023

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

Business Wire August 17, 2023

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Business Wire August 16, 2023

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

Business Wire August 11, 2023
View More News ››

Opinion & Analysis (EXPM:ATHXQ)

Companies flocking to Japan for biotech deals

The Life Sciences Report February 2, 2017

Regenerative medicine in Japan: CJ PARTNERS' Colin Lee Novick ATHX, RP, RGS, 7774:TYO, 4527:TYO, 2372:TYO

Gail Dutton August 5, 2015
View More Opinion ››

Bullboard Posts (EXPM:ATHXQ)

Interview on Fox news April 1 2020

https://www.foxnews.com/health/cell-therapy-coronavirus-treatment-cleveland-biotech-company
bmo1212 - April 1, 2020

Treasure phase iii trial

Does anybody know if this trial has commenced as yet?
pommerac - November 11, 2017

SEE JRJC China Finance Online - A Stock Primed To Quadruple;

China Finance Online - A Stock Primed To Quadruple; $13 Price Target 3D Analytics • Wed, Jun. 4 • 13 Comments •Precious-metal trading...
mumu55 - June 7, 2014

Nice Pop

In the worst trading days since Oct. 29
biovine811 - December 23, 2009
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. together with its subsidiaries, engages in the acquisition, exploration, and development of uranium ...
View More »

Podcasts